

Diagnostic Performance Evaluation Report of Test Kit against SARS-Cov-2 Variants

Prepared by:	Haitan He	Designation:	Supervisor	Date:	10-Dec-202
Reviewed by:	Serli	Designation:	Roject Manager	Date:	10-Dee-2021
Approved by:	Yabin Shi	Designation:	RD Director	Date:	1-901-22

Version: 1:0



Table Contents

1. Abstract	3
2. Study Purpose	3
3. Study Materials	4
4. Study Design and Evaluation Criteria	6
5. Study Result	7
6. Conclusion	9
7. Reference	9
Appendix A	11



Diagnostic Performance Evaluation Report of Test Kit against SARS-CoV-2 Variants

1. Abstract

Product name: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antigen
Detection Kit (Colloidal Gold-Based) (hereinafter described as "Antigen Detection Test")

Manufacturer: Nanjing Vazyme Medical Technology Co., Ltd. (hereinafter described as "Vazyme")

2. Study Purpose

To validate and evaluate the efficacy and performance for the above-mentioned product on frequent mutations of the SARS-CoV-2 virus (listed in Table 1 as follow), as manufacturer Vazyme keeps continuous attention on Covid-19 and makes necessary verification to evaluate the Antigen Detection Test can specifically interact with the recombinant nucleocapsid protein (N protein), RBD domain (RBD) and spike mutant protein (S protein) from the SARS-CoV-2 variant receptor.

Table 1 SARS-CoV-2 variant type (1)

No.	S	ARS-CoV-2 variant type	Date of designation
1	Alpha	B.1.1.7	18-Dec-2020
2	Beta	B.1.351	18-Dec-2020
3	Gamma	P.1	11-Jan-2021
4	Delta	B.1.617.2	VOI:4-Apr-2021 VOC:11-May-2021
5	Epsilon	B.1.427/B.1.429	5-Mar-2021
6	Eta,	B.1.525	17-Mar-2021
7	Kappa	B.1.617.1	4-Apr-2021
8. 8.		B.1.1.529	VUM: 24-Nov-2021 VOC: 26-Nov-2021



AL ALTONOM			
9	Lambda	C.37	14-Jun-2021
1000			

3. Study Materials

The materials used in the experiment include the antigen detection kit and the other materials shown in Tables 2 to 4.

Table 2. Materials used for recombination research of wild-type and mutant proteins of N protein

SARS-CoV-2 Targe variant viral		Sample name	Concentration tested		
Wild-type		WN			
B.1.1.7		MN1	D3L, R203K, G204R, S235F		
B.1.351		MN2 P13S, T205I			
P.1	N .	MN3	P80R, R203K, G204R, I292T	0.1 ng/mL,1	
B.1.525	protein	MN4	A12G, T205I	ng/mL, 10 ng/mL	
B.1.429+B.1.427		MN5	T205I, T391I	and 100 ng/mL	
B.1.617 (1)		MN6	R203M, D377Y		
B.1.617.2 (3)	MN7 D63G, R203M, D377Y		D63G, R203M, D377Y		
B.1.1.529		MN8	P13L, Δ31-33, RG203KR		

Table 3. Materials used for recombination research of wild-type and mutant proteins of S protein

SARS-CoV-2 Target vira		Sample Mutation site name		Concentration tested
Wild-type		ws		0.1 ng/mL,
·	S protein		H69del, V70del, Y144del,	1 ng/mL,
B.1.4.7 (MS1	N501Y, A570D, P681H, T716I, S982A, D1118H	10 ng/mL and 100 ng/mL



		D614G, D80A, D215G,	
B.1.351		E484K, N501Y,	
5.1.331	⊕ MS2	A701V, L18F, R246I,	
		Κ417Ν, Δ242-244	
B.1.526	MS3	L5F, T95I, D253G, E484K,	
В.1.320	10133	S477N, D614G, A701V	
		A67V, D614G, E484K,	
B.1.525	MS4	F888L, Δ 69, Q52R, Q677H,	
		Δ V70, Δ Y144	
B.1.429+B.1.42	MGE	D614G, L452R, S13I,	
7	MS5	W152C, W258L	
Fi., 70(H	MCC	T95I, E484K, D614G,	
Fin-796H	MS6	Ρ681Η, ΔΥ144	
		Α67V, Δ69-70, Τ95Ι,	
		G142D, Δ143-145, N211del,	
		L212I, ins214EPE, G339D,	
B.1.1.529 ⁽⁴⁾	MS7	S371L, S373P, S375F,	
B.1.1.329\\	IVIS /	K417N, N440K, G446S,	
		S477N, T478K, E484A,	
		Q493R, G496S, Q498R,	ø.
		N501Y, Y505H, T547K,	

Table 4. Materials used for recombination research of wild-type and mutant proteins of RBD

SARS-CoV-2 Target viral Sample Mutation site Concentration tested Wild-type RBD WRBD - 0.1 ng/mL,



B.1.1.7 B.1.351 P.1	5 	MRBD1	N501Y
B.1.351		MRBD2	K417N
B.1.351 P.1		MRBD3	E484K
B.1.429+B.1.427		MRBD4	L452R
B.1.617		MRBD5	L452R, E484Q
B.1.617.2		MRBD6	L452R, T487K
C.37		MRBD7	L452Q, F490S
B.1.1.529		MRBD8	G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H

4. Study Design and Evaluation Criteria

4.1 Study Design

Both sensitivity and repeatability studies are carried out to evaluate if Antigen Detection Kit (Colloidal Gold-Based) can detect both recombinant N protein, RBD and S protein wild-type and mutant proteins equally well consistently at low (0.1 ng/mL or 1 ng/mL), intermediate (10 ng/mL), and high (100 ng/mL) concentrations. For sensitivity study, 0.1 ng/mL, 1 ng/mL, 10 ng/mL and 100 ng/mL of wild-type and mutant proteins are tested one time respectively. For repeatability study, 1 ng/mL and 100 ng/mL of wild-type and mutant proteins are tested ten times respectively.

4.2 Evaluation Criteria (5)

According to the Test Procedure described in the product manual, read the results after 10 minutes. The result is invalid after 15 minutes.



Negative result: Only one red quality control line (C-line) is visible (Please see the Figure 1)

Positive result: two clear red lines are visible; one is quality control line (C-line) and the other is the T test line. (Please see the Figure 1)

Invalid result: there is no red line or there is only T test line, but no quality control line (C-line), suggesting that the item has a test error or the test result is invalid, and the item should be retested. (Please see the Figure 1)




Figure 1 Reference Diagram of Test Result

Interpretation criteria for sensitivity and repeatability, the result summarized through the line color of the cassette is defined as follow:

- Recombinant N protein wild-type protein at 0.1 ng/mL: +
- Recombinant N protein wild-type protein at 1 ng/mL: ++
- Recombinant N protein wild-type protein at 10 ng/mL: +++
- ❖ Recombinant N protein wild-type protein at 100 ng/mL: ++++
- Recombinant RBD wild-type protein at 0.1 ng/mL: -
- Recombinant RBD wild-type protein at 1 ng/mL: +
- Recombinant RBD wild-type protein at 10 ng/mL: ++
- Recombinant RBD wild-type protein at 100 ng/mL: +++
- Recombinant spike wild-type protein at 0.1 ng/mL: -
- Recombinant spike wild-type protein at 1 ng/mL: +
- Recombinant spike wild-type protein at 10 ng/mL: ++
- ❖ Recombinant spike wild-type protein at 100 ng/mL: +++

5. Study Result

5.1 Test result of N protein (referred to Table 5)

The test results show that under the testing of the recombinant wild-type and mutant proteins of N protein, the test concentration of the kit can reach 0.1ng/mL. The cassette line color rendering intensity is consistent, which means the result meets the evaluation criteria. Furthermore, this means the Antigen Detection Kit can detect the wild-type N protein of the new crown and the N



protein of different mutants without any difference.

Table 5. Sensitivity test results based on 0.1ng/mL, 1ng/mL, 10ng/mL and 100ng/mL wild-type and mutant N protein

Tested protein			Concentration						
		100 ng/mL	10 ng/mL	1 ng/mL	0.1 ng/mL				
	WN	1111	111	++	+				
	MN1	1111	411	++	+				
	MN2	++++	411	++	+				
	MN3	1111	111	++	+				
N protein	MN4	1111	111	++	+				
	MN5	++++	111	11	+				
	MN6	++++	111	+	+				
	MN7	1111	111	++	+				
	MN8	1111	111	++	+				

5.2 Test result of S protein (referred to Table 6)

The test results show that under the testing of the recombinant wild-type and mutant proteins of S protein, the test concentration of the kit can reach 1ng/mL. The cassette line color rendering intensity is consistent, which means the result meets the evaluation criteria. Furthermore, this means the Antigen Detection Kit can detect the wild-type S protein of the new crown and the S protein of different mutants without any difference.

Table 6. Sensitivity test results based on 0.1ng/mL, 1ng/mL, 10ng/mL and 100ng/mL wild-type and mutant S protein

			Concentration						
Tested protein		100 ng/mL	10 ng/mL	1 ng/mL	0.1 ng/mL				
	WS	+++	++	,+	-				
	MS1	+++	++	+	-				
	MS2	+++	++	+	-				
S protein	MS3	111	++	+					
5 protein	MS4	+++	++ .	+	- 65 65				
	MS5	+++	++	+	-				
	MS6	+++	++	+	-				
	MS7	+++	++	+	1.				

5.3 Test result of RBD (referred to Table 7)

The test results show that under the testing of the recombinant wild-type and mutant proteins of RBD, the test concentration of the kit can reach lng/mL. The cassette line color rendering intensity is consistent, which means the result meets the evaluation criteria. Furthermore, this



means the Antigen Detection Kit can detect the wild-type RBD of the new crown and the RBD of different mutants without any difference.

Table 7. Sensitivity test results based on 0.1ng/mL, 1ng/mL, 10ng/mL and 100ng/mL wild-type and mutant RBD

		Concentration						
Tested protein		100 ng/mL	10 ng/mL	1 ng/mL	0.1 ng/mL			
	WRBD	1+++	++	+	- 10			
	MRBD1	111	++	+	-			
	MRBD2	111	++	+	-			
	MRBD3	111	++	+	-			
RBD	MRBD4	111	++	+	1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -			
	MRBD5	+++	++	+	- 30			
	MRBD6	111	++	+				
	MRBD7	111	++	+				
	MRBD8	+++	++	+	-			

In addition, the test is repeated for 10 times on wild-type and mutant proteins with concentrations of 1 ng/mL and 100 ng/mL, and the results meet the evaluation criteria. The specific data is shown in **Appendix A**.

6. Conclusion

In summary, for the SARS-CoV-2 variants listed above in "Clausula 2 Study Purpose", the antigen detection kit is able to detect SARS-CoV-2 variants.

At the equivalent concentrations, the color intensity of red T lines of mutant proteins is similar to those of wild-type protein. Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2) Antigen Detection Kit (Colloidal Gold-Based) can be performed equally well, in a consistent manner against both recombinant N protein, RBD and S protein wild-type and mutant proteins that are tested in the studies. In addition, the analytical sensitivity of the Kit is 0.1 ng/mL of N protein, 1 ng/mL of RBD or S protein. And there's no invalid result.

7. Reference

- 1. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
 - 2. https://covdb.stanford.edu/
 - 3. Jamie Lopez Bernal, Nick Andrews, Charlotte Gower.et.al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. doi.org/10.1101/2021.05.22.2



- 4. Akatsuki Saito, Takashi Irie, Rigel Suzuki.et.al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Doi:10.1038/s41586-021-04266-9
- 5. Sandile Cele, Farina Karim, Gila Lustig.et.al. SARS-CoV-2 evolved during advanced HIV disease immunosuppression has Beta-like escape of vaccine and Delta infection elicited immunity. Doi: 10.1101/2021.09.14.21263564
- 6. Manual of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antigen Detection Kit (Colloidal Gold-Based)



Appendix A

Table 8: Result of repeatability study with 100 ng/mL of wild-type and mutant proteins for 10 times

C	ncentration	1, 1, 10				100 r	ıg/mL				
Tested protein		1	2	2 3	4	5	6	7	8	9	10
Acsted protein	WN	++++	++++	++++	++++	++++	1111	++++	++++	1111	++++
	MN1	++++	++++	++++	++++	++++	1111	++++	1111	1111	++++
	MN2	++++	++++	++++	++++	++++	1111	++++	++++	1111	++++
	MN3	++++	++++	++++	++++	++++	++++	++++	++++	++++	++++
N protein	MN4	++++	++++	++++	++++	1111	4111	++++	++++	++++	++++
	MN5	++++	++++	++++	++++	++++	++++	++++	++++	++++	+++
	MN6	++++	++++	++++	++++	1111	4111	++++	++++	1111	+++
	MN7	++++	1111	++++	1111	++++	++++	++++	++++	++++	+++
	MN8	1111	++++	1111	++++	++++	++++	++++	++++	1111	+++
	WS	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++
	MS1	+++	+++ -	+++	+++	+++	+++	+++	+++	+++	+++
	MS2	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++
Spike protein	MS3	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++
Spike protein	MS4	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++
	MS5	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++
	MS6	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++
	MS7	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++
	WRBD	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++
	MRBD1	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++
	MRBD2	+++	+++	+++	+++	+++	+++ ,	+++	+++	+++	+++
DDD -6:!	MRBD3	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++
RBD of spike	MRBD4	+++	+++	+++	+++	+++	+++	+++	+++	ø 1++	+++
protein	MRBD5	+++	+++	+++	+++	+++ :	+++	+++	+++	+++	+++
	MRBD6	++	+++	+++	+++	+++	+++	+++	+++	+++	+++
	MRBD7	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++
	MRBD8	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++

Table 9: Result of repeatability study with 1 ng/mL of wild-type and mutant proteins for 10 times

Concentratin Tested protein		1 ng/mL									
		1	2	3	4	5	6	7	8	9	10
N protein	WN	++	++	++	++	++	++	1++	++	++	++
	MN1	++	++	++	++	++	++:	++	++	++	++
	MN2	++	++	++	++	++	++	++	++	++	++
	MN3	++	++	++	++	++	++	++	++	++	++
	MN4	++	++	++	++	++	++	++	++	++	++



Confidentiality: [Confidential]

	1,016										
	MN5	++	++	++	++	++	++	++	++	++	++
	MN6	++	++	++	++	++	++	++	++	++	++
	MN7	++	++	++	++	++	++	++	++	++	++
	MN8	++	++	++	++	++	++	++	++	++	++
Spike protein	WS	Ť	+	+	+	+	+	+	+	+	+
	MS1	+	+ .	+	+	+	+	+	+	+	+
	MS2	+	+	+	+	+	+	+	+	+	+
	MS3	+	+	+	+	+	+	+	+	+	+
	MS4	+	+	+	+	+	+	+	+	+	+
	MS5	+	+	+	+	+	+	+	+	+	+
	MS6	+	+	+	+	+	+	+	+	+	+
	MS7	+	+	+	+	+	+	+	+	+	+
RBD of spike protein	WRBD	+	+	+	+	+	+	+	+	+	+
	MRBD1	+	+	+	+	+	+	+	+	+	+
	MRBD2	+	+	+	+	+	+	+	+	+	+
	MRBD3	+	+	+	+	+	+	+	+	+	+
	MRBD4	+	+	+	+	+	+	+	+	+	+
	MRBD5	+	+	+	+	+	+	+	+	+	+
	MRBD6	+	+	+	+	+	+	+	+ '	+	+
	MRBD7	+	+	+	+	+	+	+	+	+	+
	MRBD8	+	+	+	+	+	+	+	+	+	+

